UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported):
(Exact name of registrant as specified in charter)
(State or other jurisdiction of incorporation)
(Commission File Number) | (IRS Employer Identification No.) |
(Address of principal executive offices and zip code)
(Registrant’s telephone number including area code)
N/A
(Former Name and Former Address)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
(The Nasdaq Capital Market) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company |
If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01 Other Information
Heat Biologics, Inc. (the “Company”) is announcing commencement of a biosecurity/biodefense initiative to be initiated via its Blackhawk Bio, Inc. subsidiary. The Company recognizes the need for a versatile US-based platform to protect the United States against known or unknown future biological threats and has commenced development of such a program.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: August 17, 2021 | HEAT BIOLOGICS, INC. | |
By: | /s/ Jeffrey Wolf | |
Name: | Jeffrey Wolf | |
Title: | Chairman, President and Chief Executive Officer |
Cover |
Aug. 17, 2021 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Aug. 17, 2021 |
Entity File Number | 001-35994 |
Entity Registrant Name | Heat Biologics, Inc. |
Entity Central Index Key | 0001476963 |
Entity Tax Identification Number | 26-2844103 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 627 Davis Drive |
Entity Address, Address Line Two | Suite 400 |
Entity Address, City or Town | Morrisville |
Entity Address, State or Province | NC |
Entity Address, Postal Zip Code | 27560 |
City Area Code | (919) |
Local Phone Number | 240-7133 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, $0.0002 par value per share |
Trading Symbol | HTBX |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
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end